drugset / Trial / NCT02966522

Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis

NCT02966522 ↗

NaSingle-groupOpen-labelTreatment

Summary

To prove the organ-reversing potential of thalidomide for amyloidosis with cardiac involvement

Timeline

Start
2016-10
Primary completion
2019-09
Completion
2019-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified — —
Background Dexamethasone Small molecule — —

Indications